NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00633893,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,https://clinicaltrials.gov/study/NCT00633893,,COMPLETED,"The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)",YES,Venous Thrombosis,DRUG: Apixaban|DRUG: Placebo,"Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation, VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event., Day 1 up to 12 Months|Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation, VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 months","Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation, VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event., Day 1 up to 12 Months|Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation, VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event., Day 1 up to 12 Months|Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation, DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 Months|Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation, PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 Months|Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation, VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation)., Day 1 up to 12 Months|Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation, CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 Months|Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 Months|Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation, All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months|Adjudicated Major Bleeding During the Treatment Period - Treated Population, Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug., Day 1 up to 12 Months|Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants, Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug., Day 1 up to 12 Months|Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants, Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits., Day 1 up to 12 months|Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants, All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug., Day 1 up to 12 months|Adjudicated Total Bleeding During the Treatment Period - Treated Participants, All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug., Day 1 up to 12 months|Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation, VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints., Day 1 up to 12 Months|Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation, CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months|Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation, DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months|Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation, PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months|Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation, VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint., Day 1 up to 12 Months|Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation, CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months|Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted., Day 1 up to 12 Months",,Bristol-Myers Squibb,Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE3,2711,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CV185-057|EUDRACT: 2007-004953-27,2008-05,2012-08,2012-08,2008-03-12,2013-10-25,2013-11-25,"Alabama Clinical Therapeutics, Llc, Birmingham, Alabama, 35235, United States|Cardiovascular Consultants, Ltd., Phoenix, Arizona, 85032, United States|Robert J. Bloomberg, Md, Pc, Tempe, Arizona, 85283, United States|Fort Smith Lung Center, Fort Smith, Arkansas, 72901, United States|Beaver Medical Group, Banning, California, 92220, United States|Scripps Clinic/Scripps Health And Green Hospital, La Jolla, California, 92037, United States|Healthcare Partners Medical Group, Los Angeles, California, 90015, United States|Mission Internal Medical Group, Mission Viejo, California, 92691, United States|Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group, Palm Springs, California, 92262, United States|Indus Clinical Research Institute, Inc., Pomona, California, 91767, United States|Kaiser Permanente Medical Center, San Francisco, California, 94118, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Harbor Ucla Medical Center, Torrance, California, 90509, United States|Progressive Clinical Research, Vista, California, 92083, United States|Rocky Mountain Internal Medicine, Aurora, Colorado, 80012, United States|New West Physicians, Golden, Colorado, 80401, United States|Alfieri Cardiology, Newark, Delaware, 19713, United States|Bay Pines Va Healthcare Systems, Bay Pines, Florida, 33744, United States|Research Alliance, Inc., Clearwater, Florida, 33756, United States|St. Francis Sleep Allergy & Lung Institute, Clearwater, Florida, 33765, United States|Berma Research Group, Fort Lauderdale, Florida, 33316, United States|Healthworx, Hollywood, Florida, 33021, United States|Hematology Oncology Associates, Loxahatchee, Florida, 33470, United States|South Miami Heart Center, Miami, Florida, 33143, United States|Physicians Regional Medical Group, Naples, Florida, 34119, United States|Richard A. Mclean M.D., P.A., Plantation, Florida, 33317, United States|Tampa Clinical Research, Tampa, Florida, 33624, United States|Primary Care Of The Treasure Coast, Inc., Vero Beach, Florida, 32960, United States|Cleveland Clinic Florida, Weston, Florida, 33331, United States|Vascular Surgical Associates, Pc, Austell, Georgia, 30106, United States|Atlanta Institute For Medical Research, Inc, Decatur, Georgia, 30030, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, 30046, United States|Boise Orthopedic Clinic, Boise, Idaho, 83706, United States|Saltzer Medical Group, Nampa, Idaho, 83686, United States|Infectious Disease Of Indiana Psc, Carmel, Indiana, 46032, United States|Office Of:Eugene C. Fletcher, Md, New Albany, Indiana, 47150, United States|Heartland Vascular Medicine And Surgery, Windsor Heights, Iowa, 50324, United States|Kentucky Lung Clinic, Hazard, Kentucky, 41701, United States|Owensboro Heart & Vascular, Owensboro, Kentucky, 42303, United States|Pen Bay Medical Center, Rockport, Maine, 04856, United States|Anne Arundel Health System Research Institute, Inc., Annapolis, Maryland, 21401, United States|Cape Cod Research Institute, Hyannis, Massachusetts, 02601, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|William Beaumont Hospital, Royal Oak, Michigan, 48073, United States|Veterans Affairs Medical Center, Kansas City, Missouri, 64128, United States|Mercury Street Medical Group, Pllc, Butte, Montana, 59701, United States|Great Falls Clinic, Llp, Great Falls, Montana, 59405, United States|Internal Medical Associates Of Grand Island, P.C, Grand Island, Nebraska, 68803, United States|Creighton University Medical Center, Omaha, Nebraska, 68131, United States|Kaleida Health System, Buffalo, New York, 14209, United States|Goshen Medical Associates, Goshen, New York, 10924, United States|Sjh Cardiology Associates, Liverpool, New York, 13088, United States|Richmond University Medical Center, Staten Island, New York, 10310, United States|New York Medical College, Valhalla, New York, 10595, United States|Thomas L. Ortel, Md, Phd, Durham, North Carolina, 27710, United States|Valley Internal Medicine, Fayetteville, North Carolina, 28304, United States|Rex Healthcare, Raleigh, North Carolina, 27607, United States|Piedmont Healthcare/Research, Statesville, North Carolina, 28625, United States|Whiteville Medical Associates, P.A., Whiteville, North Carolina, 28472, United States|Wilmington Medical Research, Wilmington, North Carolina, 28401, United States|Akron General Medical Center, Akron, Ohio, 44307, United States|Community Health Care, Inc., Canal Fulton, Ohio, 44614, United States|Valley Medical Research, Centerville, Ohio, 45459, United States|Ohio State University Medical Center, Columbus, Ohio, 43210, United States|Remington Davis Inc., Columbus, Ohio, 43215, United States|Jobst Vascular Center At The Toledo Hospital, Toledo, Ohio, 43606, United States|Cor Clinical Research, Llc, Oklahoma City, Oklahoma, 73103, United States|Pma Medical Specialists, Phoenixville, Pennsylvania, 19460, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, 29414, United States|Greenville Hospital System, Greenville, South Carolina, 29615, United States|Three Rivers Medical Associates, Pa, Irmo, South Carolina, 29063, United States|Clinical Research Authority, Llc, Murrells Inlet, South Carolina, 29576, United States|Palmetto Clinical Research, Summerville, South Carolina, 29485, United States|Holston Medical Group, Bristol, Tennessee, 37620, United States|Holston Medical Group, Kingsport, Tennessee, 37660, United States|Amarillo Heart Clinical Research Institute Inc., Amarillo, Texas, 79106, United States|Corsicana Medical Research, Corsicana, Texas, 75110, United States|Ankur Doshi, Md, Houston, Texas, 77024, United States|Northwest Heart Center, Tomball, Texas, 77375, United States|Tanner Clinic, Layton, Utah, 84041, United States|University Of Utah Hospital, Salt Lake City, Utah, 84132, United States|University Of Virginia Health System, Charlottesville, Virginia, 22908, United States|Sentara York Clinical Research, Norfolk, Virginia, 23510, United States|Lake Washington Vascular, Pllc, Bellevue, Washington, 98004, United States|Franciscan Research Center, Tacoma, Washington, 98405, United States|Medical Assoicates Inc., Menomonee Falls, Wisconsin, 53051, United States|Local Institution, Capital Federal, Buenos Aires, C1426ANZ, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, 1093 AAS, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, C1180AAX, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, C1437JCP, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, C1034ACO, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, C1181ACH, Argentina|Local Institution, Coronel Suarez, Buenos Aires, B7540GHD, Argentina|Local Institution, La Plata, Buenos Aires, 1900, Argentina|Local Institution, La Plata, Buenos Aires, B1902COI, Argentina|Local Institution, Mar Del Plata, Buenos Aires, 7600, Argentina|Local Institution, San Martin, Buenos Aires, B1650CSQ, Argentina|Local Institution, Rosario, Santa Fe, S2000CVB, Argentina|Local Institution, Rosario, Santa Fe, S2000DSV, Argentina|Local Institution, Rosario, Santa Fe, S2002KDS, Argentina|Local Institution, Buenos Aires, C1122AAL, Argentina|Local Institution, Buenos Aires, C1280AEB, Argentina|Local Institution, Buenos Aires, C1431FWO, Argentina|Local Institution, Cordoba, 5000, Argentina|Local Institution, Cordoba, X5000JHQ, Argentina|Local Institution, Corrientes, 3400, Argentina|Local Institution, Garran, Australian Capital Territory, 2605, Australia|Local Institution, Kogarah, New South Wales, 2217, Australia|Local Institution, Lismore, New South Wales, 2480, Australia|Local Institution, St Leonards, New South Wales, 2065, Australia|Local Institution, Herston, Queensland, 4029, Australia|Local Institution, Kippa Ring, Queensland, 4021, Australia|Local Institution, Woolloongabba, Queensland, 4102, Australia|Local Institution, Adelaide, South Australia, 5000, Australia|Local Institution, Bedford Park, South Australia, 5042, Australia|Local Institution, Launceston, Tasmania, 7250, Australia|Local Institution, Box Hill, Victoria, 3128, Australia|Local Institution, Clayton, Victoria, 3168, Australia|Local Institution, Footscray, Victoria, 3011, Australia|Local Institution, Parkville, Victoria, 3050, Australia|Local Institution, Richmond, Victoria, 3121, Australia|Local Institution, Ringwood East, Victoria, 3135, Australia|Local Institution, Windsor, Victoria, 3181, Australia|Local Institution, Perth, Western Australia, 6000, Australia|Local Institution, Graz, 8036, Austria|Local Institution, Innsbruck, A-6020, Austria|Local Institution, Vienna, 1090, Austria|Local Institution, Vienna, 1100, Austria|Local Institution, Wien, 1090, Austria|Local Institution, Wien, 1140, Austria|Local Institution, Salvador, Bahia, 40144 900, Brazil|Local Institution, Brasilia, Distrito Federal, 70335, Brazil|Local Institution, Belo Horizonte - Mg, Minas Gerais, 30130, Brazil|Local Institution, Belo Horizonte - Mg, Minas Gerais, 30150, Brazil|Local Institution, Curitiba, Parana, 80030, Brazil|Local Institution, Curitiba, Parana, 80050, Brazil|Local Institution, Curitiba, Parana, 80810, Brazil|Local Institution, Curitiba, Parana, 81520, Brazil|Local Institution, Rio Janeiro, Rio De Janeiro, 22280, Brazil|Local Institution, Port Alegre, Rio Grande Do Sul, 90020, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90035, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90610, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 9110270, Brazil|Local Institution, Botucatu, Sao Paulo, 18618, Brazil|Local Institution, Campinas, Sao Paulo, 13083, Brazil|Local Institution, Santo Andre - Sp, Sao Paulo, 09060, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, 15015, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, 15090, Brazil|Local Institution, Rio De Janeiro, 20551, Brazil|Local Institution, Sao Paulo, 01323, Brazil|Local Institution, Sao Paulo, 01509, Brazil|Local Institution, Sao Paulo, 04005, Brazil|Local Institution, Sao Paulo, 05403, Brazil|Local Institution, Edmonton, Alberta, T5H 4B9, Canada|Local Institution, Edmonton, Alberta, T5X 3N5, Canada|Local Institution, Edmonton, Alberta, Tsa 4l8, Canada|Local Institution, Kelowna, British Columbia, V1Y 9L8, Canada|Local Institution, Victoria, British Columbia, V8R 4R2, Canada|Local Institution, Hamilton, Ontario, L8L 2X2, Canada|Local Institution, Hamilton, Ontario, L8S 4K1, Canada|Local Institution, Toronto, Ontario, M5G 2C4, Canada|Local Institution, Waterloo, Ontario, N2J 1C4, Canada|Local Institution, Windsor, Ontario, N8X 5A6, Canada|Local Institution, Montreal, Quebec, H1T 2M4, Canada|Local Institution, Montreal, Quebec, H3G 1A4, Canada|Local Institution, Montreal, Quebec, H3T 1M5, Canada|Local Institution, Pointe- Claire, Quebec, H9R 3J1, Canada|Local Institution, St. Jerome, Quebec, J7Z 5T3, Canada|Local Institution, Quebec, G1V 4G5, Canada|Local Institution, Temuco, Araucania, 4781173, Chile|Local Institution, Punta Arenas, Magallanes Antartica, 6212296, Chile|Local Institution, Independencia, Metropolitana, XXXXX, Chile|Local Institution, Santiago, Metropolitana, 7500520, Chile|Local Institution, Santiago, Metropolitana, 7600448, Chile|Local Institution, Santiago, Metropolitana, 7980378, Chile|Local Institution, Santiago, Metropolitana, 8330024, Chile|Local Institution, Vina Del Mar, Valparaiso, 2520000, Chile|Local Institution, Kladno, 272 59, Czech Republic|Local Institution, Litomysl, 570 14, Czech Republic|Local Institution, Mestec Kralove, 289 03, Czech Republic|Local Institution, Ostrava Vitkovice, 703 00, Czech Republic|Local Institution, Plzen, 323 33, Czech Republic|Local Institution, Praha 13, 158 00, Czech Republic|Local Institution, Praha 1, 110 00, Czech Republic|Local Institution, Praha 1, 118 33, Czech Republic|Local Institution, Praha 2, 120 00, Czech Republic|Local Institution, Praha 2, 121 11, Czech Republic|Local Institution, Praha 2, 128 08, Czech Republic|Local Institution, Praha 4, 140 21, Czech Republic|Local Institution, Usti Nad Orlici, 562 18, Czech Republic|Local Institution, Arhus C, 8000, Denmark|Local Institution, Braedstrup, 8740, Denmark|Local Institution, Esbjerg, 6700, Denmark|Local Institution, Frederiksberg, 2000, Denmark|Local Institution, Hellerup, 2900, Denmark|Local Institution, Herning, 7400, Denmark|Local Institution, Hilleroed, 3400, Denmark|Local Institution, Naestved, 4700, Denmark|Local Institution, Silkeborg, 8600, Denmark|Local Institution, Arras, 62022, France|Local Institution, Besancon, 25000, France|Local Institution, Brest Cedex, 29609, France|Local Institution, Clamart, 92141, France|Local Institution, Clermont-Ferrand Cedex 01, 63003, France|Local Institution, Dijon, 21079, France|Local Institution, Grenoble, 38043, France|Local Institution, Le Kremlin-Bicetre, 94275, France|Local Institution, Lille Cedex, 59020, France|Local Institution, Limoges Cedex, 87042, France|Local Institution, Lyon Cedex 03, 69437, France|Local Institution, Nantes, 44093, France|Local Institution, Saint-Priest En Jarez, 42270, France|Local Institution, Toulouse Cedex 9, 31059, France|Local Institution, Vernon, 27200, France|Local Institution, Berlin, 10117, Germany|Local Institution, Berlin, 10787, Germany|Local Institution, Berlin, 14050, Germany|Local Institution, Bochum, 44791, Germany|Local Institution, Bonn, 53115, Germany|Local Institution, Cologne, 50937, Germany|Local Institution, Dortmund, 44137, Germany|Local Institution, Dresden, 01067, Germany|Local Institution, Dresden, 01307, Germany|Local Institution, Erfurt, 99089, Germany|Local Institution, Frankfurt, 60596, Germany|Local Institution, Gottingen, 37075, Germany|Local Institution, Karlsbad, 76307, Germany|Local Institution, Krefeld, 47805, Germany|Local Institution, Ludwigshafen, 67063, Germany|Local Institution, Mannheim, 68161, Germany|Local Institution, Mannheim, 68165, Germany|Local Institution, Mannheim, 68167, Germany|Local Institution, Munchen, 80331, Germany|Local Institution, Munich, 80336, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Shatin, N.T, Hong Kong|Local Institution, Hyderabad, Andhra Pradesh, 500 082, India|Local Institution, Hyderabad, Andhra Pradesh, 500034, India|Local Institution, Ahmedabad, Gujarat, 380006, India|Local Institution, Gurgaon, Haryana, 122001, India|Local Institution, Bangalore, Karnataka, 560054, India|Local Institution, Bengaluru, Karnataka, 560017, India|Local Institution, Kochi, Kerala, 682041, India|Local Institution, Pune, Maharashtra, 411001, India|Local Institution, Mohali, Punjab, 160062, India|Local Institution, Ludhiana, Tagore Nagar, 141001, India|Local Institution, Chennai, Tamil Nadu, 600 006, India|Local Institution, Ahmedabad, 380015, India|Local Institution, Bangalore, Karnataka, 560034, India|Local Institution, Bangalore, 560052, India|Local Institution, Chennai, 600 003, India|Local Institution, Chennai, 600 006, India|Local Institution, New Dehli, 110025, India|Local Institution, Afula, 18101, Israel|Local Institution, Givataim, 53488, Israel|Local Institution, Hadera, 38101, Israel|Local Institution, Haifa, 31048, Israel|Local Institution, Haifa, 31096, Israel|Local Institution, Holon, 58100, Israel|Local Institution, Jerusalem, 91031, Israel|Local Institution, Kfar Saba, 44281, Israel|Local Institution, Kiryat Hadassah, 91120, Israel|Local Institution, Nahariya, 22100, Israel|Local Institution, Petach-Tikva, 49100, Israel|Local Institution, Safed, 13100, Israel|Local Institution, Tel Aviv, 64239, Israel|Local Institution, Tel Hashomer, 52621, Israel|Local Institution, Bollate, 20021, Italy|Local Institution, Bologna, 40138, Italy|Local Institution, Chieti Scalo, 66013, Italy|Local Institution, Cosenza, 87100, Italy|Local Institution, Ferrara, 44100, Italy|Local Institution, Firenze, 50134, Italy|Local Institution, Genova, 16128, Italy|Local Institution, Milano, 20132, Italy|Local Institution, Padova, 35128, Italy|Local Institution, Palermo, 90127, Italy|Local Institution, Pavia, 27100, Italy|Local Institution, Perugia, 06132, Italy|Local Institution, Piacenza, 29100, Italy|Local Institution, Pisa, 56124, Italy|Local Institution, Roma, 00168, Italy|Local Institution, Rozzano (Mi), 20089, Italy|Local Institution, San Daniele Del Friuli (Ud), 33038, Italy|Local Institution, Udine, 33100, Italy|Local Institution, Venezia, 30122, Italy|Local Institution, Vicenza, 36100, Italy|Local Institution, Vittorio Veneto (Tv), 31029, Italy|Local Institution, Busan, 602-702, Korea, Republic of|Local Institution, Jongno-Gu, 110-774, Korea, Republic of|Local Institution, Seoul, 120752, Korea, Republic of|Local Institution, Seoul, 135-710, Korea, Republic of|Local Institution, Seoul, 137-040, Korea, Republic of|Local Institution, Seoul, 138736, Korea, Republic of|Local Institution, Tijuana, Baja California, 22500, Mexico|Local Institution, Mexico, Distrito Federal, 06726, Mexico|Local Institution, Leon, Guanajuato, 37320, Mexico|Local Institution, Guadalajara, Jalisco, 44130, Mexico|Local Institution, Guadalajara, Jalisco, 44200, Mexico|Local Institution, Guadalajara, Jalisco, 44280, Mexico|Local Institution, Zapopan, Jalisco, 45200, Mexico|Local Institution, Monterrey, Nuevo Leon, 64000, Mexico|Local Institution, Monterrey, Nuevo Leon, 64710, Mexico|Local Institution, Culiacan, Sinaloa, 80020, Mexico|Local Institution, Culiacan, Sinaloa, 80230, Mexico|Local Institution, Xalapa, Veracruz, 91020, Mexico|Local Institution, Aguascalientes, 20230, Mexico|Local Institution, Chihuahua, 31203, Mexico|Local Institution, Durango, 34080, Mexico|Local Institution, Puebla, 72000, Mexico|Local Institution, Queretaro, 76000, Mexico|Local Institution, San Luis Potosi, 78200, Mexico|Local Institution, San Luis Potosi, 78240, Mexico|Local Institution, Alesund, 6026, Norway|Local Institution, Fredrikstad, 1606, Norway|Local Institution, Gjettum, 1346, Norway|Local Institution, Gjovik, 2819, Norway|Local Institution, Hamar, 2318, Norway|Local Institution, Oslo, 0407, Norway|Local Institution, Cavite, 4114, Philippines|Local Institution, Davao City, 8000, Philippines|Local Institution, Pasig City, 1600, Philippines|Local Institution, Quezon City, 1102, Philippines|Local Institution, Arkonska 4, 71455, Poland|Local Institution, Bialystok, 15-276, Poland|Local Institution, Bydgoszcz, 85-168, Poland|Local Institution, Bydgoszcz, 85-650, Poland|Local Institution, Bydgoszcz, 85-681, Poland|Local Institution, Gdansk, 80-803, Poland|Local Institution, Gdynia, 81-348, Poland|Local Institution, Gdynia, 81-423, Poland|Local Institution, Lodz, 90-153, Poland|Local Institution, Lublin, 20-081, Poland|Local Institution, Lublin, 20-718, Poland|Local Institution, Poznan, 61-848, Poland|Local Institution, Przeworsk, 37-200, Poland|Local Institution, Szczecin, 70-111, Poland|Local Institution, Tarnobrzeg, 39-400, Poland|Local Institution, Warsawa, 02-776, Poland|Local Institution, Warsaw, 01-809, Poland|Local Institution, Warsaw, 02-005, Poland|Local Institution, Warszawa, 01-138, Poland|Local Institution, Warszawa, 02-018, Poland|Local Institution, Wroclaw, 51-124, Poland|Local Institution, Wroclaw, 53-114, Poland|Local Institution, Guarda, 6301-857, Portugal|Local Institution, Lisboa, 1769-001, Portugal|Local Institution, San Juan, 00909, Puerto Rico|Local Institution, San Juan, 00921, Puerto Rico|Local Institution, Baia Mare, 430031, Romania|Local Institution, Bucharest, 022328, Romania|Local Institution, Bucharest, 030171, Romania|Local Institution, Bucharest, 050098, Romania|Local Institution, Targu Mures, 540136, Romania|Local Institution, Arkhangelsk, 163045, Russian Federation|Local Institution, Kemerovo, 650002, Russian Federation|Local Institution, Moscow, 105077, Russian Federation|Local Institution, Moscow, 111539, Russian Federation|Local Institution, Moscow, 119049, Russian Federation|Local Institution, Moscow, 127473, Russian Federation|Local Institution, Novosibirsk, 630055, Russian Federation|Local Institution, Novosibirsk, 630090, Russian Federation|Local Institution, Rostov-On Don, 344022, Russian Federation|Local Institution, Ryazan, 390026, Russian Federation|Local Institution, Saint Petersburg, 192242, Russian Federation|Local Institution, Saint-Petersburg, 196247, Russian Federation|Local Institution, Saint-Petersburg, 199106, Russian Federation|Local Institution, Samara, 443010, Russian Federation|Local Institution, Saratov, 410012, Russian Federation|Local Institution, Saratov, 410028, Russian Federation|Local Institution, St Petersburg, 194044, Russian Federation|Local Institution, Tomsk, 634012, Russian Federation|Local Institution, Yaroslavl, 150062, Russian Federation|Local Institution, Singapore, 169608, Singapore|Local Institution, Singapore, 308433, Singapore|Local Institution, Bloemfontein, Free State, 9301, South Africa|Local Institution, Centurion, Gauteng, 0157, South Africa|Local Institution, Parktown, Gauteng, 2193, South Africa|Local Institution, Pretoria, Gauteng, 0083, South Africa|Local Institution, Pretoria, Gauteng, 0084, South Africa|Local Institution, Durban, Kwa Zulu Natal, 4001, South Africa|Local Institution, Pietermaritzburg, Kwa Zulu Natal, 3201, South Africa|Local Institution, Bellville, Western Cape, 7530, South Africa|Local Institution, George, Western Cape, 6529, South Africa|Local Institution, Somerset West, Western Cape, 7130, South Africa|Local Institution, Worcester, Western Cape, 6850, South Africa|Local Institution, Torrevieja, Alicante, 03186, Spain|Local Institution, Badalona, Barcelona, 08916, Spain|Local Institution, Majadahonda, Madrid, 28222, Spain|Local Institution, San Sebastian De Los Reyes, Madrid, 28702, Spain|Local Institution, Cadiz, 11009, Spain|Local Institution, Getafe, 28905, Spain|Local Institution, Girona, 17007, Spain|Local Institution, L'Hospitalet De Llobregat, 08907, Spain|Local Institution, Leon, 24008, Spain|Local Institution, Madrid, 28007, Spain|Local Institution, Madrid, 28029, Spain|Local Institution, Madrid, 28040, Spain|Local Institution, Madrid, 28041, Spain|Local Institution, Mourente, 36071, Spain|Local Institution, Pamplona, 31008, Spain|Local Institution, Salamanca, 37007, Spain|Local Institution, Sant Boi De Llobregat, 08830, Spain|Local Institution, Tarragona, 43007, Spain|Local Institution, Toledo, 45071, Spain|Local Institution, Valencia, 46026, Spain|Local Institution, Chernihiv, 14034, Ukraine|Local Institution, Dnipropetrovsk, 49000, Ukraine|Local Institution, Donetsk, 83045, Ukraine|Local Institution, Ivano-Frankivsk, 76008, Ukraine|Local Institution, Ivano-Frankivsk, 76018, Ukraine|Local Institution, Kharkiv, 61018, Ukraine|Local Institution, Kyiv, 03680, Ukraine|Local Institution, Lviv, 79010, Ukraine|Local Institution, Odesa, 65117, Ukraine|Local Institution, Ternopil, 46000, Ukraine|Local Institution, Vinnytsia, 21018, Ukraine|Local Institution, Zaporizhzhia, 69035, Ukraine|Local Institution, Aberdeen, Aberdeenshire, AB25 2ZN, United Kingdom|Local Institution, Romford, Essex, RM7 0AG, United Kingdom|Local Institution, London, Greater London, SE5 9RS, United Kingdom|Local Institution, London, Greater London, SW17 0QT, United Kingdom|Local Institution, Manchester, Greater Manchester, M23 9LT, United Kingdom|Local Institution, Hull, Humberside, HU3 2JZ, United Kingdom|Local Institution, Nottingham, Nottinghamshire, NG7 2UH, United Kingdom|Local Institution, Bury St. Edmunds, Suffolk, IP30 9QU, United Kingdom|Local Institution, Coventry, West Midlands, CV2 2DX, United Kingdom|Local Institution, Dudley, West Midlands, DY1 2HQ, United Kingdom",
